Cereno Scientific expands collaboration with Dr. Michael Holinstat as Director of Translational Research
Cereno Scientific today announced that Dr. Michael Holinstat, Ph.D., FAHA, takes on the role as Director of Translational Research at Cereno. The role marks a further focus on the importance of Cereno’s early-stage development, for which Dr. Holinstat leads the two current preclinical programs at the University of Michigan. The expansion of the Cereno team adds expertise and secures knowledge important to the company’s portfolio development.
“We are happy to have Dr. Michael Holinstat join Cereno to spear head our preclinical stage assets. He has extensive experience in early-stage drug development, especially within cardiovascular diseases,” says Sten R. Sörensen, CEO at Cereno Scientific.
“I look forward to working closer with the Cereno team and their early-stage development assets. With my experience within cardiovascular diseases and network, I hope I can positively contribute to Cereno’s portfolio development ,” says Dr. Michael Holinstat.
Dr. Michael Holinstat received his Ph.D. in pharmacology from the University of Illinois, Chicago, and completed postdoctoral training at Vanderbilt University in Nashville. His research interests include areas such as thrombosis, pharmacology and hematology. Dr. Holinstat is an Associate Professor in Pharmacology and lead the translational programs in drug development in Hemostasis and Thrombosis in the Department of Pharmacology at the University of Michigan. Dr. Holinstat has built a "state of the art" laboratory to investigate the effects of different pharmacological principles on platelets and coagulation both in vitro and in vivo.
Dr. Holinstat’s primary employment is as an associate professor at the Department of Pharmacology, Internal Medicine (Division of Cardiovascular Medicine), and Vascular Surgery at University of Michigan Medical School.
For further information, please contact:
Daniel Brodén, CFO
Phone: +46 768 66 77 87
Email: info@cerenoscientific.com
http://www.cerenoscientific.com/
About Cereno Scientific AB
Cereno Scientific is a clinical stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH) and thrombotic indications. CS1 is an HDAC (Histone DeACetylase) inhibitor that acts as an epigenetic modulator with anti-thrombotic, anti-inflammatory, anti-fibrotic and pressure-relieving properties, all relevant for PAH. A clinical phase II study for CS1 in PAH is expected to be initiated in September 2021 under its US FDA granted orphan drug designation (ODD) status. In addition, Cereno has two promising preclinical development programs targeted at treating cardiovascular diseases. The company is headquartered in AstraZeneca’s BioVenture Hub, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Swedish Spotlight Stock Market (CRNO B). More information on www.cerenoscientific.com.